Vitamin D implementation among MS patients affects the cytokine levels, reducing the synthesis of pro-inflammatory cytokines and elevating the concentrations of the anti-inflammatory cytokines, for example, transforming growth factor-beta (TGF-β) or interleukin-10 (IL-10) [20,21,22]. This evidence concerns the gene IL10 and myeloid sarcoma.